COPD

Chronic Obstructive Pulmonary Disease (COPD) ? Pipeline Review, H1 2013

Mon, 18 Mar 2013 00:00:00 GMT

Chronic Obstructive Pulmonary Disease (COPD) ? Pipeline Review, H1 2013 Global Markets Direct?s, ''Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2013'', provides an overview of the indication?s therapeutic pipeline. This report provides information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD). Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, Half Year is built using data and information sourc...

Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H2, 2012

Tue, 20 Nov 2012 00:00:00 GMT

Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H2, 2012 GlobalData''s clinical trial report, ?Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H2, 2012" provides data on the Chronic Obstructive Pulmonary Disease (COPD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Obstructive Pulmonary Disease (COPD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of t...

Epidemiology: COPD in China ? Aging, population growth, and increased survival will drive up prevalent cases over the next decade

Tue, 02 Oct 2012 00:00:00 GMT

Datamonitor's research shows that out to 2010, COPD will continue to be a major threat to Chinese adults. The number of prevalent cases of COPD will increase substantially between 2011 and 2021, increasing from approximately 42 million to nearly 56 million. This increase will be driven by demographic changes over the forecast period, including increased survival and a larger aged population.Features and benefitsGain insight to market potential, including a robust 10-year epidemiology forecast of COPD prevalent cases in China.Understand the key epidemiologic risk factors associated with COPD in China.HighlightsThe...

Chronic Obstructive Pulmonary Disease (COPD) ? Pipeline Review, H2 2012

Fri, 31 Aug 2012 00:00:00 GMT

Chronic Obstructive Pulmonary Disease (COPD) ? Pipeline Review, H2 2012 Global Markets Direct?s, ''Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2012'', provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD). ''Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2012'' is buil...

Global Markets for Asthma and COPD Drugs

Tue, 14 Aug 2012 00:00:00 GMT

REPORT HIGHLIGHTSThe global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs was valued at $34.9 billion in 2011. This figure is projected to reach $38 billion in 2012 and $47.1 billion in 2017, increasing at a five-year compound annual growth rate (CAGR) of 4.4%.Combination asthma/COPD drugs are expected to be worth $17.4 billion in 2012 and should reach $21.3 billion in 2017, a CAGR of 4.1%.The segment made up of asthma drugs is projected to increase from $15.3 billion in 2012 to $20.2 billion in 2017, a CAGR of 5.7%.COPD drugs are expected to increase from $5.3 billion in 2012 to $5.6 billion in 2017, a...

Product Profiles: COPD ? Novel combinations race to the finish

Fri, 18 May 2012 00:00:00 GMT

COPD is a growing market with a dynamic pipeline aiming to address unmet needs. A number of pipeline products threaten established drug classes. Once-daily bronchodilator combinations in particular are expected to offer a novel treatment option with high clinical and commercial potential and a number of companies are racing to be the first to reach the market.Features and benefitsAccess Datamonitor’s independent clinical and commercial assessment of marketed brands and key pipeline agents for COPD.Understand what it takes to differentiate a product in COPD treatment and how the pipeline threatens current market leaders.Assess how pipeline...

R&D Trends: COPD ? Simplified therapies are gaining traction

Wed, 14 Mar 2012 00:00:00 GMT

Datamonitor identified 109 products in development for COPD in 2012. Later stages of the pipeline are made up of familiar classes for COPD, or combinations thereof, with four LABA/LAMA combinations in Phase III. Earlier stages of the pipeline show more diversity, with numerous novel anti-inflammatory therapies seen in preclinical and Phase I development.Features and benefitsSupport R&D decision making by understanding the competitive dynamics of the pipeline.Analyze clinical trial design, with a focus on how companies can use endpoints to differentiate their products.Assess novel early-stage approaches and the future of treatment in COPD, w...

Market and Product Forecasts: COPD in China ? Novel therapies to see patient potential limited by high cost

Wed, 14 Dec 2011 00:00:00 GMT

The increasing prevalence of COPD and new therapies will boost the Chinese COPD market from $204m to $317m by 2020. Spiriva will become the market leader from 2013 and maintain the position through 2020, owing to its wide application across all disease severities. A number of novel products will increase the product offering on the market, with most pipeline products aimed at more severe patients.Features and benefitsAccess Datamonitor’s patient-based COPD market forecast in China, with transparent methodology and clear assumptions.Explore the current and future market size of COPD in China and see which...

Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD

Mon, 31 Oct 2011 00:00:00 GMT

GBI Research’s report, Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD, provides an in-depth analysis of patient recruitment scenario for major indications under respiratory diseases. The report analyzes number of clinical trials conducted for major indications. The report provides information about total number of clinical trials conducted by phase, geography, major sponsors and clinical trials conducted per year. Analysis of total number of patients recruited for major indications is done. The report analyzes total number of patients r...

Product Profiles: Asthma/COPD ? Novel combinations edge closer to market

Fri, 28 Oct 2011 00:00:00 GMT

IntroductionDespite a number of well-established therapies, the asthma/COPD pipeline remains highly active. A number of products have progressed in the pipeline and significant new data have been presented at this year’s respiratory conferences. Numerous product launches are expected in the next 10 years, which will fragment the markets, although a handful of companies will maintain market dominance.Features and benefitsAccess Datamonitor’s independent clinical and commercial assessment of marketed brands and key pipeline agents for asthma and COPD.Understand to what extent current and future therapies satisfy th...

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Wed, 31 Aug 2011 00:00:00 GMT

GlobalData, the industry analysis specialist, has released its new report, Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market. The report identifies the key trends shaping and driving the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the r...

Epidemiology: COPD ? Aging population and stable smoking rates to raise case numbers

Wed, 17 Aug 2011 00:00:00 GMT

IntroductionIn 2010, Datamonitor estimates that there were about 69.5 million total prevalent cases of chronic obstructive pulmonary disease (COPD) in people aged over 40 in the seven major markets(the US, Japan, France, Germany, Italy, Spain, and the UK). Approximately 54% of cases were mild, 38% were moderate, and 8% were severe or very severe.Features and benefitsGain insight into market potential, including a robust 10-year epidemiology forecast of chronic obstructive pulmonary disease prevalent cases.Understand the key epidemiolo...

The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016

Fri, 27 May 2011 00:00:00 GMT

IntroductionThe report provides an in-depth analysis of the respiratory franchise. It also highlights the key R&D trends that may influence treatment sales and includes a thorough analysis of the competitive dynamics of leading brands within each indication, enabling the reader to identify growth of the leading brands, key drug classes and leading players through 2016.Features and benefitsQuantify patient potential and assess treatment trends and sales patterns across the major respiratory indications in the seven major ...

Epidemiology: COPD in China

Fri, 01 Apr 2011 00:00:00 GMT

Datamonitor's research shows that out to 2020, COPD will continue to be a major threat to Chinese adults. The number of prevalent cases of COPD will increase substantially between 2010 and 2020, increasing from approximately 42 million to nearly 56 million. This increase will be driven by demographic changes over the forecast period, including increased survival and a larger aged population.Gain insight to market potential, including a robust 10-year epidemiology forecast of COPD prevalent cases in China.Understand the key epidemiologic risk factors associated with COPD in China.<...

Epidemiology: COPD in India

Fri, 01 Apr 2011 00:00:00 GMT

In 2010, almost 24 million adults over the age of 40 in India had COPD. Datamonitor expects this number to increase 34% to approximately 32 million by 2020. COPD is predominately a disease of men and only 40% of cases in India occur in women. Over the forecast period, the growth in the number of total prevalent cases of COPD will be primarily driven by demographic changes.Gain insight to market potential, including a robust 10-year epidemiology forecast of COPD prevalent cases in India.Understand the key epidemiologic risk factors associated with COPD in India.

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Assessment and Market Forecasts to 2017

Sun, 05 Dec 2010 00:00:00 GMT

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Assessment and Market Forecasts to 201GlobalData, the industry analysis specialist, has released its new report, Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global COPD market. The report identifies the key trends shaping and driving the global COPD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides v...

Forecast Insight: Asthma/COPD ? Pipeline potential outweighs downward pressure from generics

Thu, 07 Oct 2010 00:00:00 GMT

Datamonitor estimates that in 2009 asthma/COPD sales reached $21.5 billion in the seven major markets. The next 10 years will see the dynamic pipeline fracture a market currently dominated by a handful of blockbuster brands. While patent expiries will create downward pressure, Datamonitor forecasts the asthma/COPD market will reach sales of $24.2 billion by 2019, with a 2009-2019 CAGR of 1.2%.Insight into market potential including current market trends, changing regulations and recent pipeline developments10 year country, indication, and device specific forecasts for individual products, taking into account competiti...

Asthma/COPD Market Forecast

Wed, 29 Sep 2010 00:00:00 GMT

IntroductionThis model contains a 10 year country, indication, and device specific forecasts for individual products used in asthma and COPD, taking into account competitive positioning and key market events.Reasons to PurchaseQuantify the size and scope of the asthma and COPD market and the changing market dynamics from 2009-2019Understand asthma and COPD market trends including drivers of success and the impact of changing regulationsGain insight into the recent advances in the asthma and COPD pipeline and access forecasts of 13 novel products...

Commercial Insight: Asthma/COPD in Australia

Thu, 20 May 2010 00:00:00 GMT

IntroductionThe Australian asthma/COPD market grew from $278m in 2006 to $333m in 2009. Its growth will slow considerably with the market projected to reach revenues of $354m in 2019. As new drugs launched will be me-too products or combinations of existing classes, Datamonitor assumes that these will be priced similarly to current brands in order to receive reimbursement, leading to a stabilizing market.ScopeForecast for marketed and late-stage pipeline asthma/COPD products in Australia.Assessment of Australia-specific drivers and resistors likely to impact the market.Future market outlook for individual products taking into account key market events, ...

Asthma and COPD Market Forecast

Wed, 10 Jun 2009 00:00:00 GMT

IntroductionAlthough the respiratory market has expanded considerably from 2004 to 2008, growth in the seven major markets is slowing down from 2009 to 2011, after which sales will decline due to patent expiries of leading brands. Growth is driven by the expansion of sales in existing classes, the launch of major new products with safety and convenience advantages, and the results of several landmark trials.Reasons to PurchaseIdentify key opportunities and threats that will impact the use and uptake of new and existing productsQuantify the future size and scope of the asthma/COPD market and predict the performance of ke...